These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 7685291)
1. The AMPA receptor antagonist NBQX does not alter the motor response induced by selective dopamine agonists in MPTP-treated monkeys. Luquin MR; Obeso JA; Laguna J; Guillén J; Martínez-Lage JM Eur J Pharmacol; 1993 Apr; 235(2-3):297-300. PubMed ID: 7685291 [TBL] [Abstract][Full Text] [Related]
2. Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys. Luquin MR; Guillén J; Martínez-Vila E; Laguna J; Martínez-Lage JM Eur J Pharmacol; 1994 Mar; 253(3):215-24. PubMed ID: 7911084 [TBL] [Abstract][Full Text] [Related]
3. NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats. Wachtel H; Kunow M; Löschmann PA Neurosci Lett; 1992 Aug; 142(2):179-82. PubMed ID: 1280793 [TBL] [Abstract][Full Text] [Related]
5. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597 [TBL] [Abstract][Full Text] [Related]
6. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys. Gomez-Mancilla B; Bédard PJ Exp Neurol; 1992 Aug; 117(2):185-8. PubMed ID: 1354166 [TBL] [Abstract][Full Text] [Related]
7. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Klockgether T; Turski L; Honoré T; Zhang ZM; Gash DM; Kurlan R; Greenamyre JT Ann Neurol; 1991 Nov; 30(5):717-23. PubMed ID: 1662477 [TBL] [Abstract][Full Text] [Related]
8. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys. Blanchet P; Bédard PJ; Britton DR; Kebabian JW J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395 [TBL] [Abstract][Full Text] [Related]
10. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease. Löschmann PA; Lange KW; Kunow M; Rettig KJ; Jähnig P; Honoré T; Turski L; Wachtel H; Jenner P; Marsden CD J Neural Transm Park Dis Dement Sect; 1991; 3(3):203-13. PubMed ID: 1835581 [TBL] [Abstract][Full Text] [Related]
11. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys. Goulet M; Madras BK J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310 [TBL] [Abstract][Full Text] [Related]
12. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Clarke CE; Boyce S; Sambrook MA; Stahl SM; Crossman AR Naunyn Schmiedebergs Arch Pharmacol; 1988 Jul; 338(1):35-8. PubMed ID: 2907097 [TBL] [Abstract][Full Text] [Related]
13. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Marin C; Jimenez A; Bonastre M; Chase TN; Tolosa E Synapse; 2000 Jun; 36(4):267-74. PubMed ID: 10819904 [TBL] [Abstract][Full Text] [Related]
14. The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Temlett JA; Chong PN; Oertel WH; Jenner P; Marsden CD Eur J Pharmacol; 1988 Nov; 156(2):197-206. PubMed ID: 2977118 [TBL] [Abstract][Full Text] [Related]
15. Facilitation of dopamine D1 receptor- but not dopamine D1/D2 receptor-dependent locomotion by glutamate antagonists in the reserpine-treated mouse. Starr MS; Starr BS Eur J Pharmacol; 1993 Dec; 250(2):239-46. PubMed ID: 7906652 [TBL] [Abstract][Full Text] [Related]
16. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys. Nomoto M; Fukuda T Adv Neurol; 1993; 60():119-22. PubMed ID: 8093574 [No Abstract] [Full Text] [Related]
18. Pharmacological characterization of non-NMDA subtypes of glutamate receptor in the neonatal rat hemisected spinal cord in vitro. Zeman S; Lodge D Br J Pharmacol; 1992 Jun; 106(2):367-72. PubMed ID: 1382781 [TBL] [Abstract][Full Text] [Related]
19. CNQX but not NBQX prevents expression of amphetamine-induced place preference conditioning: a role for the glycine site of the NMDA receptor, but not AMPA receptors. Mead AN; Stephens DN J Pharmacol Exp Ther; 1999 Jul; 290(1):9-15. PubMed ID: 10381753 [TBL] [Abstract][Full Text] [Related]
20. Characterization of the metabotropic glutamate receptor in mouse cerebellar granule cells: lack of effect of 2,3-dihydroxy-6-nitro-7-sulphamoylbenzo(F)-quinoxaline (NBQX). Suzdak PD; Sheardown MJ; Honoré T Eur J Pharmacol; 1993 May; 245(3):215-20. PubMed ID: 7687559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]